When will Fresenius Medical Care report earnings and why does it matter for FME.DE stock?

Fresenius Medical Care reports earnings on **24 Feb 2026**; this matters for FME.DE stock because results and guidance on clinic volumes, device sales and margins will drive near-term price movement and may change analyst views on valuation.

What is Meyka AI's price outlook for FME.DE stock?

Meyka AI's forecast model projects **€44.36** at one year for FME.DE stock, implying about **7.81%** upside from the current **€41.15**. Forecasts are model-based projections and not guarantees.

Which financial metrics should investors watch in the report for FME.DE stock?

Watch EPS versus consensus, organic revenue growth in dialysis services, operating margin trends, free cash flow and net debt-to-EBITDA. FME.DE stock currently shows PE **16.55**, free cash flow yield **14.79%**, and net debt/EBITDA **2.93x**.

What are the main risks that could move FME.DE stock after earnings?

Main risks include weaker-than-expected clinic volumes, adverse reimbursement news, contract losses in the U.S., and FX pressure. Any signs of margin erosion or guidance cuts could push FME.DE stock lower.

DE Stocks

FME.DE Fresenius Medical Care XETRA 19 Feb 2026 earnings preview: catalysts

ByDanny Kontos February 19, 2026February 19, 2026

FME.DE stock trades at €41.15 on XETRA intraday as Fresenius Medical Care prepares to report earnings on 24 Feb 2026. Investors will focus on margin trends in dialysis services, U.S. hospital contract renewals and product sales growth. The stock is down 0.21 euros today with a day range of €40.74–€41.31, but year-to-date performance is essentially flat. With EPS at €2.44 and a trailing PE of 16.55, the upcoming report could shift sentiment for a healthcare name that mixes stable cash flow and leverage.